Moreover, as most patients in this study received a combination of EGFR-Abs and chemotherapy, we investigated what proportion of the cancer cells harboured these drivers to assess if a genetic resistance-gap also occurs in mCRCs that acquired resistance to chemotherapy and EGFR-Ab or if this only arises with single-agent cetuximab. Here, EGFR is linked to cancer.